GLAND Gland Pharma Q1 FY26 results (Apr–Jun 2025) and concall
Gland Pharma delivered a strong start to FY26, characterized by a significant turnaround in its Cenexi subsidiary and robust margin expansion in the base business. The company is aggressively pivoting towards complex injectables and the GLP-1 market, with substantial capacity expansions underway. Despite some volatility in Enoxaparin supplies and seasonal shutdowns expected in Q2 for Cenexi, management remains confident in achieving mid-teen growth for the US market and maintaining consolidated margins in the 24-25% range.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 1,063 | 1,011 | 1,030 | 1,039 |
| EBITDA | 364 | 391 | 394 | 359 |
| Net profit | 282 | 295 | 290 | 269 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
